Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH
Delluc A (1), Antic D (2), Lecumberri R (3), Ay C (4), Meyer G (5), Carrier M (6).
(1) EA 3878, Department of Internal Medicine and Chest Diseases, Centre hospitalier universitaire de Brest, Hôpital de la Cavale Blanche, Brest, France.
(2) Clinic for Hematology, Lymphoma Center, Clinical Center Serbia, Medical Faculty, Department for Internal Medicine, University of Belgrade, Belgrade, Serbia.
(3) Hematology Service, Clínica Universidad de Navarra, Pamplona, Spain.
(4) Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
(5) Department of Respiratory Disease, Hôpital Européen Georges Pompidou, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMRS 970 and CIC 1418, Paris, France.
(6) Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Venous thromboembolism (VTE) can be the ﬁrst manifestation of cancer.
Although four prospective studies have suggested that limited occult cancer screening might be adequate after a ﬁrst unprovoked VTE [1–4], there is no
evidence that it should be applied to all VTE patients (provoked events, unusual site VTE, etc.).
Furthermore, other uncertainties, such as which tests should be performed or whether occult cancer screening should be performed after a recurrent VTE event, still remain.
Our objective is to provide guidance on the different management options for clinicians facing these frequent challenges.
CITATION J Thromb Haemost. 2017 Aug 5. doi: 10.1111/jth.13791